Recent Advances in Inflammatory Bowel Disease

References

• Sandler RS, Sandler DP, McDonnell CM, et al. Childhood exposure to environmental tobacco smoke and the risk of ulcerative colitis. Am J Epidemiol 1992; 135: 603–9.
   Google Scholar
• Vessey M, Jewell D, Smith A, et al. Chronic inflammatory bowel disease, cigarette smoking, and use of oral contraceptives: Findings in a large cohort of women of childbear-ing age. Br Med J 1986; 292: 1101–3.
   Google Scholar
• Thomas GAO, Rhodes J, Green JT. Inflammatory bowel disease and smoking: a review. Am J Gastroenterol 1998; 93: 144–9.
   Google Scholar
• Harries AD, Baird A, Rhodes J. Non-smoking: a feature of ulcerative colitis. Br Med J 1982; 284: 706.
   Google Scholar
• Franceschi S, Panza E, Lavecchia C, et al. Nonspecific inflammatory bowel disease and smoking. Am J Epidemiol 1987; 125: 445–52.
   Google Scholar
• Silverstein MD, Lashner BA, Hanauer SB, et al. Cigarette smoking in Crohn's disease. Am J Gastroenterol 1989; 84: 31–3.
   Google Scholar
• Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990; 98: 1123–28.
   Google Scholar
• Timmer A, Sutherland LR, Martin F. Oral contraceptives use and smoking are risk factors for relapse of Crohn's disease. Gastroenterology 1998; 114: 1143–50.
   Google Scholar
• Podolsky DK, Isselbacher KJ. Composition of human colonic mucin. Selective alteration in inflammatory bowel disease. J Clin Invest 1983; 72:142–53.
   Google Scholar
• Cope GF, Heatley RV, Kelleher J. Smoking and colonic mucus in ulcerative colitis. Br Med J 1986; 293: 481.
   Google Scholar
• Raouf A, Parker N, Ryder S, et al. Ion exchange chromatography of purified colonic glycoproteins in inflammatory bowel disease: absence of a selective subclass defect. Gut 1991; 32: 1139–45.
   Google Scholar
• Benoni C, Prytz H. Effects of smoking on the urine excretion of oral 51Cr EDTA in ulcerative colitis. Gut 1998; 42: 656–5.
   Google Scholar
• Sher ME, Bank S, Greenberg R, et al. The influence of cigarette smoking on cytokine levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 1999; 5: 73–78.
   Google Scholar
• Madretsma S, Wolters LM, van Dijk JP, et al. In-vivo effect of nicotine on cytokine production by human non-adherent mononuclear cells. Eur J Gastroenterol Hepatol 1996; 8: 1017–20.
   Google Scholar
• Russell GM, Engels LG, Muris JW, et al. 'Modern life' in the epidemiology of inflammatory bowel disease: a case-control study with specific emphasis on nutritional factors. Eur J Gastroenterol Hepatol 1998; 10: 243–9.
   Google Scholar
• Ainly C, Cason J, Slavin BM, et al. The influence of zinc status and malnutrition on immunological function in Crohn's disease. Gastroenterology 1991; 100: 1616–25.
   Google Scholar
• O'Morain C, Segal A, Levi A. Elemental diet as a primary treatment of acute Crohn's disease: a controlled study. Br Med J1984; 288:1859–62.
   Google Scholar
• Lochs H, Steinhardt HJ, Klaus-Wentz B, et al. Comparison of enteral nutrition and drug treatment in active Crohn's disease. Gastroenterology 1991; 101: 881–8.
   Google Scholar
• Griffiths AM, Ohlsson A, Scherman PM, et al. Meta-analysis of enteral nutrition as a primary treatment of active disease. Gastroenterology 1995; 108: 1056–67.
   Google Scholar
• Fernandez-Benares F, Cabre E, Esteve-Comas M, et al. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical results. J Parent Ent Nutr 1995; 19: 356–60.
   Google Scholar
• Teahon K, Smethurst P, Pearson M, et al. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology 1991;101:84–9.
   Google Scholar
• Boyko EJ, Theis MK, Vaughan TL, et al. Increased risk of inflammatory bowel disease associated with oral contraceptive use. Am J Epidemiol 1994; 140: 268–78.
   Google Scholar
• Kaufmann HJ, Taubin HL. Nonsteroidal antiinflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107: 513–6.
   Google Scholar
• Bjarnason I, Hayllar J, MacPherson AJ, et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832–47.
   Google Scholar
• Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000–16.
   Google Scholar
• Arndt H, Palitzsch KD, Scholmerich J. Leucocyte endothelial cell adhesion in indometha-cin induced intestinal inflammation is correlated with faecal pH. Gut 1998; 42: 380–6.
   Google Scholar
• Demling L. Is Crohn's disease caused by antibiotics? Hepatogastroenterology 1994; 41: 549–551.
   Google Scholar
• Mate-Jimenez J, Correa-Estan JA, Perez-Miranda et al. Tonsillectomy and inflammatory bowel disease location. Eur J Gastroenterol Hepatol 1996; 8: 1185–8
   Google Scholar
• Rutgeerts P, D'Haens G, Hiele M, et al. Appendectomy protects against ulcerative colitis. Gastroenterology 1994; 106: 1251–3.
   Google Scholar
• Russel MG, Dorant E, Brummer RJ, et al. Appendectomy and the risk of developing ulcerative colitis or Crohn's disease: results of a large case-control study. South Limburg Inflammatory Bowel Disease Study Group. Gastroenterology 1997; 113: 377–82.
   Google Scholar
• Wurzelmann JI, Lyles CM, Sandler RS. Childhood infections and the risk of inflammatory bowel disease. Dig Dis Sci 1994; 39: 555–60.
   Google Scholar
• Gilat T, Hacoben D, Lilos P, et al. Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand J Gastroenterol 1987; 22: 1009–24.
   Google Scholar
• Theis MK, Boyko EJ. Patient perceptions of causes of inflammatory bowel disease. Am J Gastroenterol 1994; 89: 1920.
   Google Scholar
• Cohen S, Williamson GM. Stress and infectious disease in humans. Psychol Bull 1991; 109: 5–24.
   Google Scholar
• Herbert TB, Cohen S. Stress and immunity in humans: a meta-analytic review. Psychosom Med 1993; 55: 364–79.
   Google Scholar
• Wakefield AJ, Dhillon AP, Rowles PM, et al. Pathogenesis of Crohn's disease: Multifocal gastrointestinal infarction. Lancet 1989; 2: 1057–62.
   Google Scholar
• Wakefield AJ, Sankey EA, Dhillon AF, et al. Granulomatous vasculitis in Crohn's disease. Gastroenterology 1991; 100: 1279–87.
   Google Scholar
• Wakefield AJ, Sawyer AM, Hudson M, et al. Smoking, the oral contraceptive pill, and Crohn's disease. Dig Dis Sci 1991; 36: 47–52.
   Google Scholar
• Monsen U, Brostrom O, Nordenvall B, et al. Prevalence of IBD among relatives of patients with ulcerative colitis. Scand J Gastroenterol 1987; 22: 214–8.
   Google Scholar
• Farmer RG, Michener WM. Association of inflammatory bowel disease in families. Front Gastrointest Res 1986; 11:17–26.
   Google Scholar
• Tysk C, Lindberg E, Jarnerot G, et al. Ulcerative colitis and Crohn's disease in unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut 1988; 29: 990–96.
   Google Scholar
• Orholm M, Munkholm P, Langholz E, et al. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991; 324: 84–8.
   Google Scholar
• Ekbom A, Helmick C, Zack M, et al. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology 1991; 100: 350–58.
   Google Scholar
• Bayless TM, Tokayer AZ, Polito JM, et al. Crohn's disease: concordance for site and clinical type in affected family memberspotential hereditary influences. Gastroenterol-ogy 1996; 111: 573–9.
   Google Scholar
• Polito JM, Rees RC, Childs B, et al. Preliminary evidence for genetic anticipation in Crohn's disease. Lancet 1996; 347: 798–800.
   Google Scholar
• Elmgreen J, Both H, Binder V. Familial occurrence of complement dysfunction in Crohn's disease: correlation of intestinal symptoms and hypercatabolism of complement. Gut 1985; 26: 151–157.
   Google Scholar
• Fiocchi C, Roche JK, Michener WM. High prevalence of antibodies to intestinal epithelial antigens in patients with inflammatory bowel disease and their relatives. Ann Intern Med 1989; 110: 786–94.
   Google Scholar
• Hollander D, Vadheim C, Brettholz E, et al. Increased intestinal permeability in patients with Crohn's disease and their relatives. Ann Intern Med 1986; 105: 883–85.
   Google Scholar
• Koltun WA, Tilberg AF, Page MJ, et al. Bowel permeability is improved in Crohn's disease after ileocolectomy. Dis Colon Rectum 1998; 41: 687–90.
   Google Scholar
• Gusella JF, Podolsky DK. Inflammatory bowel disease: is it in the genes? Gastroenterology 1998; 115: 1286–89.
   Google Scholar
• McConnell RB, Vadheim CM. Inflammatory bowel disease. In: King RA, Rotter JL, and Motulsky AO, eds. The Genetic Basis of Common Disease. Pp. 326–48. Oxford: Oxford University Press, 1992.
   Google Scholar
• Satsangi J. The Genetics of Inflammatory Bowel Disease. In: Rampton D, ed. Inflammatory Bowel Disease: Clinical Diagnosis and Management. Pp. 3–15. London: Martin Dunitz, 2000.
   Google Scholar
• Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996; 347: 1212–17.
   Google Scholar
• Asakura H, Tsuchiya M, Aiso S, et al. Association of the human lymphocyte-DR2 antigen with Japanese ulcerative colitis. Gastroenterology 1982; 82: 413–8.
   Google Scholar
• Futami S, Aoyama N, Honsako Y, et al. HLA-DRB1*1502 allele subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression. DigDis Sci 1995; 40: 814–8.
   Google Scholar
• Toyoda H, Wang S-J, Yang H-J, et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993; 104: 741–8.
   Google Scholar
• Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997; 112:1845–53.
   Google Scholar
• Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology2000; 118: 274–8.
   Google Scholar
• Mansfield JC, Holden H, Tarlow JK, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106: 637–42.
   Google Scholar
• Satsangi J, Jewell DP. Are cytokine gene polymorphisms important in the pathogenesis of inflammatory bowel disease? Eur J Gastroenterol Hepatol 1996; 8: 97–99.
   Google Scholar
• Plevy SE, Targan SR, Yang H, et al. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology 1996; 110: 1053–60.
   Google Scholar
• Kyo K, Parkes M, Takei Y, et al. Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3. Hum Mol Genet 1999; 8: 307–11.
   Google Scholar
• Yang H, Vora DK, Targan SR, et al. Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease. Gastroenterology 1995; 109: 440–8.
   Google Scholar
• Hugot J-P, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996; 379: 821–23.
   Google Scholar
• Ohmen JD, Yang H, Yamomoto KK et al. Susceptibility locus for IBD on chromosome 16 has a role in Crohn's disease but not in ulcerative colitis. Hum Mol Gen 1996; 5: 167983.
   Google Scholar
• Cavanaugh JA, Callen DF, Wilson SR, et al. Analysis of Australian Crohn's disease pedigrees refines the localization for susceptibility to inflammatory bowel disease on chromosome 16. Ann Human Genet 1998; 2: 291–8.
   Google Scholar
• Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996; 14: 199–202.
   Google Scholar
• Rioux JD, Daly MJ, Green T, et al. Absence of linkage between inflammatory bowel disease and selected loci on chromosome 3, 7, 12, and 16. Gastroenterology 1998; 115: 1062–65.
   Google Scholar
• Cho JH, Nicolae DL, Gold LH, et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci USA 1998; 95: 7502–7.
   Google Scholar
• Sartor RB. Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis and experimental intestinal inflammation. In: Kirsner JB and Shorter RG, eds. Inflammatory Bowel Disease. 4th ed. Pp. 96–124. Baltimore: Williams & Wilkins, 1995.
   Google Scholar
• Mourelle M, Salas A, Guarnier F, et al. Stimulation of transforming growth factor P1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology 1998; 114: 519–26.
   Google Scholar
• Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998; 115: 1405–13.
   Google Scholar
• Turunen UM, Farkkila MA, Hakala K, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998; 115: 1072–78.
   Google Scholar
• Levine J, Ellis CJ, Furne JK, et al. Fecal hydrogen sulfide production in ulcerative colitis. Am J Gastroenterol 1998; 93: 83–7.
   Google Scholar
• Fukushima Y, Kawata Y, Hara H, et al. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int J Food Microbiol 1998; 42: 39–44.
   Google Scholar
• Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103–8.
   Google Scholar
• Harper PH, Lee EC, Kettlewell MG, et al. Role of faecal stream in the maintenance of Crohn's colitis. Gut 1985; 26: 279–84.
   Google Scholar
• Rutgeerts P, Geboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 2: 771–74.
   Google Scholar
• D'Haens G, Geboes K, Peeters M, et al. Early lesions caused by infusion of intestinal contents in excluded ileum of Crohn's disease. Gastroenterology 1998; 114: 262–7.
   Google Scholar
• Sartor RB. Enteric microflora in IBD: pathogens or commensuals? Inflammatory Bowel Dis 1997; 3: 230–235.
   Google Scholar
• Cong BY, Brandwein SL, McCabe RP, et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBr mice: increased T helper cell type 1 response and abiliaty to transfer disease. J Exp Med 1998; 187: 855–64.
   Google Scholar
• Ekbom A, Wakefield AJ, Zack M, et al. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994; 344: 508–10.
   Google Scholar
• Iizuka M, Nakagomi O, Chiba M, et al. Absence of Measles virus in Crohn's disease. Lancet 1995; 345: 199.
   Google Scholar
• Liu Y, Van Kruinigen HJ, West AB, et al. Immunocytochemical evidence of Listeria, Eschericha coli, and Streptococcus antigen in Crohn's disease. Gastroenterology 1995; 108: 1396–404.
   Google Scholar
• Afzal MA, Minor PD, Begley J, et al. Absence of measles-virus genome in inflammatory bowel disease. Lancet 1998; 351: 646–7.
   Google Scholar
• Peltola H, Patja A, Leinkki P, et al. No evidence for measles, munps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. Lancet 1998; 351: 1327–8.
   Google Scholar
• Chiodini RJ, Kruiningen HJV, Thayer WR, et al. Possible role of mycobacteria in inflammatory bowel disease: An unclassified mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci 1984; 29: 1073–79.
   Google Scholar
• Coloe PJ, Wilkes CR, Lightfoot D, et al. Isolation of Mycobacterium paratuberculosis in Crohn's disease. Aust Microbiol 1986; 7: 188A.
   Google Scholar
• Chiodini RJ. Crohn's disease and the mycobacterioses: a review and comparison of two disease entities. Clin Microbiol Rev 1989; 2: 90–117.
   Google Scholar
• Rowbotham DS, Mapstone NP, Trejdosiewicz LK, et al. Mycobacterium paratuberculosis DNA not detected in Crohn's disease tissue by fluorescent polymerase chain reaction. Gut 1995; 37: 660–7.
   Google Scholar
• Suenaga K, Yokoyama Y, Okazaki K, et al. Mycobacteria in the intestine of Japanese patients with inflammatory bowel disease. Am J Gastroenterol 1995; 90: 76–80.
   Google Scholar
• Afdhal NH, Long A, Lennon J, et al. Controlled trial of antimycobacterial therapy in Crohn's disease. Dig Dis Sci 1991; 36: 449–53.
   Google Scholar
• Giu GPH, Thomas PRS, Tizard MLV, et al. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. JAntimicro Chemother 1997; 39: 393–400.
   Google Scholar
• Thomas GA, Swift GL, Green JT, et al. Controlled trial of antituberculosis chemotherapy in Crohn's disease: a five-year follow up study. Gut 1998; 42: 497–500
   Google Scholar
• Sartor RB. Role of intestinal microflora in initiation and perpetuation of inflammatory bowel disease. Can J Gastroenterol 1990; 4: 271–277.
   Google Scholar
• Saxon A, Shanahan F, Landers C, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990; 86: 202–10.
   Google Scholar
• Takahashi F, Das KM. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis. J Clin Invest 1985; 76: 311–8.
   Google Scholar
• Duerr RH, Targan SR, Landers CJ, et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991; 100: 138591.
   Google Scholar
• Shanahan F, Duerr RH, Rotter JI, et al. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology 1992; 103: 456–61.
   Google Scholar
• Vecchi M, Binchi MB, Sinico RA, et al. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: sensitivity, specificity and recognition of putative antigens. Digestion 1994; 55: 34–9.
   Google Scholar
• Sandborn WJ, Landers CJ, Tremaine WJ, et al. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol 1995; 90: 740–7.
   Google Scholar
• Das KM, Dasgupta A, Mandal A, et al. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanisms for ulcerative colitis. J Immunol 1993; 150: 248793.
   Google Scholar
• Das KM, Vecchi M, Sakamaki S. A shared and unique epitope on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990; 98: 464–9.
   Google Scholar
• Bhagat S, Das KM. A shared and unique epitope in the human colon, eye and joint detected by a monoclonal antibody. Gastroenterology 1994; 107: 103–108.
   Google Scholar
• Geng X, Biancone L, Dai HH, et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 1998; 114: 912–22.
   Google Scholar
• Pallone F, Fais S, Squarcia O, et al. Activation of peripheral blood and lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut 1987; 28: 74553.
   Google Scholar
• Schreiber S, MacDermott RP, Raedler A, et al. Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology 1991; 101: 1020–30.
   Google Scholar
• Pirzer U, Schonhaar A, Fleischer B, et al. Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancet 1991; 338: 1238–9.
   Google Scholar
• Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841–45.
   Google Scholar
• Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refrcatory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998; 93: 442–8.
   Google Scholar
• Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 1997; 92: 876–9.
   Google Scholar
• Kugathasan S, Willis J, Dahms BB, et al. Intrinsic hyperreactivity of mucosal T cells to interleukin-2 in pediatric Crohn's disease. J Pediatr 1998; 133: 675–81.
   Google Scholar
• Boirivant M, Pica R, DeMaria R, et al. Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. J Clin Invest 1996; 98: 2616–22.
   Google Scholar
• Ueyama H, Kiyohara T, Sawada N, et al. High Fas ligand expression on lymphocytes in lesions of ulcerative colitis. Gut 1998; 43: 48–55.
   Google Scholar
• Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology 1998; 114: 433–40.
   Google Scholar
• MacDermott RP, Nash GS, Nahm MH. Antibody secretion by human intestinal mono-nuclear cells from normal controls and inflammatory bowel disease patients. Immunol Invest 1989; 18: 449–57.
   Google Scholar
• MacDermott RP, Nash GS, Auer IO, et al. Alterations in serum immunoglobulin G subclasses in patients with ulcerative colitis and Crohn's disease. Gastroenterology 1989; 96: 764–8.
   Google Scholar
• Kett K, Rognum TO, Brandtzaeg P. Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon. Gastroenterology 1987; 93: 919–24.
   Google Scholar
• Saverymuttu SH, Lavender JP, Hodgson HJ, et al. Assessment of disease activity in inflammatory bowel disease: a new approach using 111In granulocyte scanning. Br Med J 1983; 287: 1751–3.
   Google Scholar
• Mahida YR, Perkins AC, Frier M, et al. Monoclonal antigranulocyte antibody imaging in inflammatory bowel disease: a preliminary report. Nucl Med Commun 1992; 13: 330–5.
   Google Scholar
• Handy LM, Ghosh S, Ferguson A. Investigation of neutrophil migration into the gut by cytology of whole gut lavage fluid. Eur J Gastroenterol Hepatol 1995; 7: 53–8.
   Google Scholar
• McAlindon ME, Gray T, Galvin A, et al. Differential lamina propria cell migration via basement membrane pores of inflammatory bowel disease mucosa. Gastroenterology 1998; 115: 841–8.
   Google Scholar
• Knutson L, Ahrenstedt O, Odlind B, et al. The jejunal secretion of histamine is increased in active Crohn's disease. Gastroenterology 1990; 98: 849–54.
   Google Scholar
• Weksler BB. Platelets. In: Gallin JI, Goldstein IM, and Snyderman R, eds. Inflamation: Basic Principles and Clinical Correlates. 2nd ed. Pp. 727–46. New York: Raven Press, 1992.
   Google Scholar
• Harries AD, Fitzsimons E, Fifield R, et al. Platelet count: a simple measure of activity in Crohn's disease. Br Med J 1983; 286: 1476.
   Google Scholar
• Collins CE, Cahill MR, Newland AC, et al. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994; 106: 840–5.
   Google Scholar
• Collins CE, Rampton DS. Review article: platelets in inflammatory bowel disease— pathogenetic role and therapeutic implications. Aliment Pharmacol Ther 1997; 11: 237–47.
   Google Scholar
• Rampton DS, Collins CE. Review article: thromboxanes in inflammatory bowel disease— pathogenic and therapeutic implications. Aliment Pharmacol Ther 1993; 7: 357–67.
   Google Scholar
• Stack WA, Jenkins D, Vivet P, et al. Lack of effectiveness of the platelet activating factor antagonist SR27417A in patients with active ulcerative colitis: a randomized controlled trial. Gastroenterology 1998; 115: 1340–45.
   Google Scholar
• Mahida YR, Patel S, Gionchetti P, et al. Macrophage subpopulations in lamina propria of normal and inflamed colon and terminal ileum. Gut 1989; 30: 826–34.
   Google Scholar
• Mahida YR, Wu KC, Jewell DP. Characterization of antigen-presenting activity of intestinal mononuclear cells isolated from normal and inflammatory bowel disease colon and ileum. Immunology 1988; 65: 543–9.
   Google Scholar
• Muzzucchelli L, Hauser C, Zgraggen K, et al. Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol 1994; 144: 997–1007.
   Google Scholar
• Daig R, Andus T, Aschenbrenner E, et al. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996; 38: 216–2.
   Google Scholar
• Cominelli F, Nast CC, Clark BD, et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990; 86: 972–80.
   Google Scholar
• Mahida YR, Wu KC, Jewell DP. Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease. Gut 1989; 30: 1362–70.
   Google Scholar
• Rugtveit J, Haraldsen G, Hogasen AK, et al. Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14+L1+ monocyte-derived cells. Gut; 37: 367–73.
   Google Scholar
• Mahida YR. Intestinal macrophages in inflammatory bowel disease. In: Scholmerick J, Goebell H, and Andus T, eds. Inflammatory Bowel Disease — from Bench to Bedside. Pp. 93–6. Kluwer: Academic Publishers, 1997.
   Google Scholar
• Mahida YR. Mechanisms of host protection and inflammation in the gastrointestinal tract. J R Coll Physicians Lond 1997; 31: 493–7.
   Google Scholar
• Bocker U, Damiao A, Holt L, et al. Differential expression of interleukin 1 receptor antagonist isoforms in human intestinal epithelial cells. Gastroenterology 1998; 115: 142638.
   Google Scholar
• Meijssen MA, Brandwein SL, Reinecker HC, et al. Alteration of gene expression by intestinal epithelial cells precedes colitis in interleukin-2-deficient mice. Am J Physiol 1998; 274: G472–9.
   Google Scholar
• Strater J, Wellisch I, Riedl S, et al. CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 1997; 113: 160–7.
   Google Scholar
• Rudi J, Kuck D, Strand S, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J Clin Invest 1998; 102: 1506–14.
   Google Scholar
• Kim JM, Eckmann L, Savidge TC, et al. Apoptosis of human intestinal epithelial cells after bacterial invasion. J Clin Invest 1998; 102: 1815–23.
   Google Scholar
• Strong SA, Pizarro TT, Klein JS, et al. Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells. Gastroenterology 1998; 114: 1244–56.
   Google Scholar
• Stallmach A, Schuppan D, Riese HH, et al. Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology 1992; 102: 1920–29.
   Google Scholar
• Graham MF, Drucker DEM, Diegelmann RF, et al. Collagen synthesis by human intestinal smooth muscle cells in culture. Gastroenterology 1987; 92: 400–405.
   Google Scholar
• Pender SLF, Breese EJ, Gunther U, et al. Suppression of T-cell-mediated injury in human gut by interleukin-10: role for metalloproteinases. Gastroenterology 1998; 115: 573–83.
   Google Scholar
• Panes J, Granger DN. Leucocyte-endothelial interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998; 114: 1066–90.
   Google Scholar
• Binion DG, West GA, Ina K, et al. Enhanced leucocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 1997; 112: 1895–1907.
   Google Scholar
• Binion DG, West GA, Volk EE, et al. Acquired increased in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998; 352: 1742–46.
   Google Scholar
• Strobach RS, Ross AH, Markin RS, et al. Neural patterns in inflammatory bowel disease: an immunohistochemical survey. Mod Pathol 1990; 3: 488–93.
   Google Scholar
• Davis DR, Dockerty MB, Mayo CW. The myenteric plexus in regional enteritis: a study of the number of ganglion cells in the ileum in 24 cases. Surg Gynecol Obstet 1955; 101: 208–16.
   Google Scholar
• Koch TR, Carney JA, Go VL. Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases. Dig Dis Sci 1987; 32: 369–76.
   Google Scholar
• Goldin E, Karmeli F, Selinger Z, et al. Colonic substance P levels are increased in ulcerative colitis and decreased in chronic severe constipation. Dig Dis Sci 1989; 34: 754–7.
   Google Scholar
• Kubota Y, Petras RE, Ottaway CA, et al. Colonic vasoactive intestinal peptide nerves in inflammatory bowel disease. A digitized morphometric immunohistochemical study. Gastroenterology 1992; 102: 1242–51.
   Google Scholar
• Bernstein CN, Robert ME, Eysselein VE. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 1993; 88: 908–13.
   Google Scholar
• Mantyh CR, Vigna SR, Bollinger RR, et al. Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. Gastroenterology 1995; 109: 850–60.
   Google Scholar
• Bjorck S, Dahlstrom A, Ahlman H. Topical treatment of ulcerative proctitis with lidocaine. Scand J Gastroenterol 1989; 24: 1061–72.
   Google Scholar
• McAlindon ME, Mahida YR. Cytokines and the gut. Eur J Gastroenterol Hepatol 1997; 9:1045–50.
   Google Scholar
• Casini-Raggi V, Kam L, Chong YL, et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease: a novel mechanism of chronic intestinal inflammation. J Immunol 1995; 154: 2434–40.
   Google Scholar
• Cominelli F, Nast CC, Duchini A, et al. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992; 103: 65–71.
   Google Scholar
• Schreiber S, Heinig T, Thiele HG, et al. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 1434–44.
   Google Scholar
• Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1995; 24: 475–507.
   Google Scholar
• Breese E, Braegger CP, Corrigan CJ, et al. Interleukin-2- and interferon-secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993; 78: 127–131.
   Google Scholar
• Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995; 101: 428–35.
   Google Scholar
• Fiocchi C. Cytokines. In: MacDermott RP and Stenson WF, eds. Inflammatory Bowel Disease. Pp 137. New York: Elsevier, 1992.
   Google Scholar
• Eckmann L, Kagnoff MF, Fierer J. Epithelial cells secrete the chemokine interleukin-8 in response to bacterial entry. Infect Immun 1993; 61: 4569–74.
   Google Scholar
• McCormick BA, Colgan SP, Delp-Archer C, et al. Salmonella typhimurium attachment to human intestinal epithelial monolayers: transcellular signalling to subepithelial neutrophils. J Cell Biol 1993; 123: 895–907.
   Google Scholar
• Mahida YR, Makh S, Hyde S, et al. Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. Gut 1996; 38: 337–47.
   Google Scholar
• Dubucquoi S, Janin A, Klein O, et al. Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease. Gut 1995; 37: 242–46.
   Google Scholar
• Brynskov J, Tvede N, Andersen CB, et al. Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut 1992; 33: 55–8.
   Google Scholar
• Matsuura T, West GA, Klein JS, et al. Soluble interleukin 2 and CD8 and CD4 receptors in inflammatory bowel disease. Gastroenterology 1992; 102: 2006–14.
   Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029–35.
   Google Scholar
• Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-a in Crohn's disease. Lancet 1997; 349: 521–24.
   Google Scholar
• McAlindon ME, Hawkey CJ, Mahida YR. Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 1998; 42: 214–9.
   Google Scholar
• Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin-10 (rHuIL-10) in chronic active Crohn's disease. Gastroenterology 2000; 119: 1461–72.
   Google Scholar
• Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117: 58–64.
   Google Scholar
• Dignass AU, Podolsky DK. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor. Gastroenterology 1993; 105: 1323–32.
   Google Scholar
• Wright NA, Poulsom R, Stamp G, et al. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology 1993; 194: 12–20.
   Google Scholar
• Babyatasky MW, deBeaumont M, Thim L, et al. Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology 1996; 110: 489–97.
   Google Scholar
• Finch PW, Pricolo V, Wu A, et al. Increased expression of keratinocyte growth factor messenger RNA associated with inflammatory bowel disease. Gastroenterology 1996; 110: 441–51.
   Google Scholar
• Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factor a and P in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996; 110: 975–84.
   Google Scholar
• Rampton DS, Hawkey CJ. Prostaglandins and ulcerative colitis. Gut 1984; 25: 1399–13.
   Google Scholar
• Singer II, Kawka DW, Schloemann S, et al. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998; 115: 297–36.
   Google Scholar
• Reuter BK, Asfaha S, Buret A, et al. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996; 98: 2076–85.
   Google Scholar
• Laursen LS, Naesdal J, Bukhave K, et al. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 1990; 335: 683–5.
   Google Scholar
• Roberts WG, Simon TJ, Berlin RG, et al. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 1997; 112: 725–32.
   Google Scholar
• Hawkey CJ, Dube LM, Rountree LV, et al. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. Gastroenterology 1997; 112: 718–24.
   Google Scholar
• Simmonds NJ, Allen RE, Stevens TRJ, et al. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 1992; 103: 186–96.
   Google Scholar
• McKenzie SJ, Baker MS, Buffington GD, et al. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 1996; 98: 136–41.
   Google Scholar
• Millar AD, Rampton DS, Chander CL, et al. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut 1996; 39: 40715.
   Google Scholar
• Boughton-Smith NK, Evans SM, Hawkey CJ, et al. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 1993; 342: 338–40.
   Google Scholar
• Middleton SJ, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. Lancet 1993; 341: 465–6.
   Google Scholar
• Singer II, Kawka DW, Scott S, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996; 111: 871–85.
   Google Scholar
• Kolios G, Rooney N, Murphy CT, et al. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: modulation by T lymphocyte derived cytokines. Gut 1998; 43: 56–63.
   Google Scholar
• Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEBJ1992; 6: 305164.
   Google Scholar
• Roediger WEW. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet 1980; 2: 712–5.
   Google Scholar
• Harig JM, Soergel KH, Komorowski RA, et al. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med 1989; 320: 23–8.
   Google Scholar
• Breuer RI, Buto SK, Christ ML, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report. Dig Dis Sci 1991; 36: 185–7.
   Google Scholar
• Burgio VL, Fais S, Boirivant M, et al. Peripheral monocyte and naive T-cell recruitment and activation in Crohn's disease. Gastroenterology 1995; 109: 1029–38.
   Google Scholar
• Malizia G, Calabrese A, Cottone M, et al. Expression of leucocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology 1991; 100: 150–9.
   Google Scholar
• Koizumi M, King N, Lobb R, et al. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 1992; 103: 840–7.
   Google Scholar
• Rosenberg WMC, Prince C, Kaklamanis L, et al. Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease. Lancet 1995; 345: 1205–9.
   Google Scholar
• Yacyshyn BR, Lazarovits A, Tsai V, et al. Crohn's disease, ulcerative colitis, and normal intestinal lymphocytes express integrins in dissimilar patterns. Gastroenterology 1994; 107: 1364–71.
   Google Scholar
• Nielsen OH, Langholz E, Hendel J, Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease. Dig Dis Sci 1994; 39: 1918–23.
   Google Scholar
• Yacyshyn BR, Chey W, Goff B, et al. Double-blinded,randomized, placebo-controlled trial of the remission inducing and steroid sparing properties of two schedules of ISIS 2302 (ICAM-1 antisense) in active, steroid-dependent Crohn's disease. Gastroenterology 2000; 118: A570.
   Google Scholar
• Elson CO. Experimental models of intestinal inflammation. New insights into mechanisms of mucosal homeostasis. In: Ogra PL, Mestecky J, Lamm ME, Strober W, and McGhee FR, eds. Handbook of Mucosal Immunology. Pp.1007-24. San Diego: Academic Press, 1999.
   Google Scholar
• Elson CO, Beagley KW, Sharmanov AT, et al. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol 1996; 157: 2174–85.
   Google Scholar
• Bhan AK, Mizoguchi E, Smith RN, et al. Lessons for human inflammatory bowel disease from experimental models. Current Opin Gastroenterol 1999; 15: 285–90.
   Google Scholar
• Pizarro TT, Arseneau KO, Cominelli F. Novel mouse models to study pathogenic mechanisms of Crohn's disease. Am J Physiol Gastrointest Liver Physiol2000; 278: G665–G669.
   Google Scholar
• Sartor RB, Cromartie WJ, Powell DW, et al. Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments. Gastroenterology 1985; 89: 587–95.
   Google Scholar
• Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 235964.
   Google Scholar
• Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human 2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945–53.
   Google Scholar
• Ma A, Datta M, Margosian E, et al. T cells, but not B cells, are required for bowel inflammation in interleukin 2-deficient mice. J Exp Med 1995; 182: 1567–72.
   Google Scholar
• Wittig B, Schwarzler C, Fohr N, et al. Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J Immunol 1998; 161: 1069–73.
   Google Scholar
• Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281–90.
   Google Scholar
• Ehrhardt RO, Ludviksson BR, Gray B, et al. Induction and prevention of colonic inflammation in IL-2-deficient mice. J Immunol 1997; 158: 566–73.
   Google Scholar
• Liu Z, Geboes K, Colpaert S, et al. Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45Rbhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions. J Immunol 2000; 164: 6005–14.
   Google Scholar
• Neurath MF, Fuss I, Kelsall BL, et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 1996; 183: 260516.
   Google Scholar
• Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737–42.
   Google Scholar
• Hollander GA, Simpson SJ, Mizoguchi E, et al. Severe colitis in mice with aberrant thymic selection. Immunity 1995; 3: 27–38.
   Google Scholar
• Mizoguchi A, Mizoguchi E, Chiba C, et al. Role of appendix in the development of inflammatory bowel disease in TCR-mutant mice. J Exp Med 1996; 184: 707–15.
   Google Scholar
• Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161: 5733–44.
   Google Scholar
• Baribault H, Penner L, Iozzo RV, et al. Colorectal hyperplasia and inflammation in keratin 8-deficient FVB/N mice. Genes Dev 1994; 8: 2964–73.
   Google Scholar
• Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995; 270: 1203–7.
   Google Scholar
• Bush TG, Savidge TC, Freeman TC, et al. Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell 1998; 93: 189–201.
   Google Scholar
• Mashio H, Wu DC, Podolsky DK, et al. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996; 274: 262–5.
   Google Scholar
• Kontoyiannis D, Pasparakis M, Pizarro TT, et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999; 10: 387–98.
   Google Scholar
• Sturiale S, Barbara G, Qiu B, et al. Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc Natl Acad Sci U S A 1999; 96: 11653–8.
   Google Scholar
• Madara JL, Podolsky DK, King NW, et al. Characterization of spontaneous colitis in cotton-top tamarins (Saguinus oedipus) and its response to sulfasalazine. Gastroenterology 1985; 88: 13–9.
   Google Scholar
• Stonerook M, Weiss HS, Rodriguez MA, et al. Temperature-metabolism relations in the cotton-top tamarin (Saguinus oedipus) model of ulcerative colitis. J Med Primatol 1994; 23: 16–22
   Google Scholar
• Kornbluth AA, Salomon P. Sacks HS, et al. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol 1993; 16: 215–16.
   Google Scholar
• Salomon P, Kornbluth A, Aisenberg J, et al. How effective are current drugs for Crohn's disease? A meta-analysis. J Clin Gastroenterol 1992; 14: 211–15.
   Google Scholar
• Sachar DB. Maintenance therapy in ulcerative colitis and Crohn's disease. J Clin Gastroenterol 1995; 20: 117–22.
   Google Scholar
• Greenfield SM, Punchard NA, Teare JP, et al. The mode of action of the aminosalicylates in inflammatory bowel disease. Ailment Pharmacol Ther 1993; 7: 369–83.
   Google Scholar
• Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994; 344: 859–61.
   Google Scholar
• Molin L, Stendahl O. The effect of sulfasalazine and its active components on human polymorphonuclear leucocyte function in relation to ulcerative colitis. Acta Medica Scand 1979; 206: 451–7.
   Google Scholar
• Nielsen OH, Verspaget HW, Elmgreen J. Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicyclic acid. Ailment Pharmacol Ther 1988; 2: 203–11.
   Google Scholar
• Burress GC, Musch MW, Jurivich DA, et al. Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells. Gastroenterology 1997; 113: 1474–79.
   Google Scholar
• Yang F, De Villiers WJS, McClain CJ, et al. Mesalamine modulates nuclear factor-kB/IkB-a in CACO-2 cells: A novel mechanism of action. Gastroenterology 1997; 112: 4407A.
   Google Scholar
• Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicyclic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118: 5409
   Google Scholar
• Willoughby CP, Cowan RE, Gould SR, et al. Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis. Scand J Gastroenterol Suppl 1988; 148: 40–4.
   Google Scholar
• Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed-release 5-aminosalicyclic acid (mesalamine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988; 29: 669–74.
   Google Scholar
• Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed-release 5-aminosalicyclic acid (mesalamine) and sulphasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94: 1383–89.
   Google Scholar
• Rachmilewitz D. Coated mesalazine (5-aminosalicyclic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989; 298: 8286.
   Google Scholar
• Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847–869.
   Google Scholar
• Malchow H, Ewe K, Brandes JW. Et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249–266.
   Google Scholar
• Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113: 1465–73.
   Google Scholar
• Farrell RJ, Falchuk KR. Double therapy for IBD better than single therapy? The issue is not how but how much. Inflamm Bowel Dis 1999; 5: 68–71
   Google Scholar
• Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997; 92: 1867–71.
   Google Scholar
• Green JR, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology 1998; 114: 15–22.
   Google Scholar
• Hanauer SB (for the U.S. PENTASA Enema Study Group): Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. Inflamm Bowel Disease 1998; 4: 79–83.
   Google Scholar
• Sutherland LR. Topical treatment of ulcerative colitis. Med Clin North Am 1990; 74: 11931.
   Google Scholar
• Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998; 114: 23–28.
   Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 4947: 1041–48.
   Google Scholar
• Marion JF, Present DH. The modern medical management of acute severe ulcerative colitis. Eur J Gastroenterol Hepatol 1997; 9: 831–5.
   Google Scholar
• Angeli A, Masera RG, Sartori ML, et al. Modulation of cytokines of glucocorticoid action. Ann NY Acad Sci 1999; 876: 210–20.
   Google Scholar
• Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: Inhibition of NFKB activity through induction of IKB synthesis. Science 1995; 270: 286–90.
   Google Scholar
• Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of IKBa in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283–6.
   Google Scholar
• Goulding NJ, Euzger HS, Butt SK, et al. Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. Inflamm Res 1998; 47: S158–165.
   Google Scholar
• Goppelt-Struebe M. Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids. Biochem Pharmacol 1997; 53: 1389–95.
   Google Scholar
• Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360–62.
   Google Scholar
• Kuritzkes R, Shanahan F. Corticosteroid therapy. In: Gitnick G, ed. Steroids and inflammatory bowel disease: diagnosis and treatment. Pp. 299–321. Tokyo: Igaku-Shoin, 1990.
   Google Scholar
• Lofberg R. New steroids for inflammatory bowel disease. Inflamm Bowel Dis 1995; 1: 13541.
   Google Scholar
• Dahlberg E, Thalen A, Brattsand R, et al. Correlation between chemical structure, receptor binding, and biological activity in some novel, highly active, 16a, 17a-acetyl-substituted glucocorticoids. Mol Pharmacol 1984; 25: 70–8.
   Google Scholar
• Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990; 4: 407–14.
   Google Scholar
• Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842–5.
   Google Scholar
• Bar-Meir S, for the Israeli Budesonide Study Group. Budesonide versus prednisone in the treatment of active Crohn's disease. Gastroenterology 1998; 115: 835–40.
   Google Scholar
• Ferguson A, Campieri M, Doe W, et al. Oral budesonide as maintenance therapy in Crohn's disease—results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998; 12: 175–83.
   Google Scholar
• D'Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylpred-nisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther 1998; 12: 419–24.
   Google Scholar
• Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticos-teroid-induced osteoporosis. N Engl J Med 1997; 337: 382–7.
   Google Scholar
• Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292–9.
   Google Scholar
• Floren CH, Ahren B, Bengtsson M, et al. Bone mineral density in patients with Crohn's disease during long-term treatment with azathioprine. J Intern Med 1998; 243: 123–6.
   Google Scholar
• Robinson RJ, Krzywicki T, Almond L, et al. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. Gastroenterology 1998; 115: 36–41.
   Google Scholar
• Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000; 118: 279–88.
   Google Scholar
• Rockwell S, Irvin CG, Neaderland MH. Inhibition of delayed hypersenstivity by metronidazole and misonidazole. Int JRadiat Oncol Biol Phys 1983; 9: 701–706.
   Google Scholar
• Yoshimura T, Kurita C, Usami E, et al. Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells. Chemotherapy 1996; 42: 459–464.
   Google Scholar
• Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071–75.
   Google Scholar
• Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982; 83: 550–62.
   Google Scholar
• Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984; 79: 533–40.
   Google Scholar
• Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 161721.
   Google Scholar
• Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Am J Gastroenterol 1999; 94: 674–78.
   Google Scholar
• Prantera C, Berto E, Scribano ML, et al. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol 1998; 30: 602–6.
   Google Scholar
• Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 1998; 12: 53–56.
   Google Scholar
• Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005–13.
   Google Scholar
• Sanborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl 1998; 225: 92–99
   Google Scholar
• Korelitz B, Hanauer S, Rutgeerts P, et al. Post-operative prophylaxis with 6MP, 5-ASA or placebo in Crohn's disease: A 2-year multicenter trial. Gastroenterology 1998; 114: A1011.
   Google Scholar
• Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999; 117: 527–35.
   Google Scholar
• Kader HA, Theoret Y, Tolia V, et al. A prospective randomized double blind placebo controlled study to assess the efficacy of intravenous loading of azathioprine in children and adolescents with inflammatory bowel disease. Gastroenterology 2000; 118: A118.
   Google Scholar
• Cattan S, Lemann M, Thuillier F, et al. 6-mercaptopurine levels and study of blood lymphocyte subsets during azathioprine treatment of Crohn's disease. Gastroenterol Clin Biol 1998; 22: 160–7.
   Google Scholar
• Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401–6.
   Google Scholar
• Colonna T, Korelitz BI. The role of leucopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994; 89: 362–6
   Google Scholar
• Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705–13.
   Google Scholar
• Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basus for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608–14.
   Google Scholar
• Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000; 42: 628–32.
   Google Scholar
• Colombel JF, Ferrari N, Debuysere H, et al. Genotypic Analysis of Thiopurine S-Methyltransferase in Patients With Crohn's Disease and Severe Myelosuppression During Azathioprine Therapy. Gastroenterology 2000; 118: 1025–1030.
   Google Scholar
• Lowry PW, Franklin CL, Weaver AL, et al. Investigation of a potential drug interaction between azathioprine/6-mercaptopurine and sulfasalazine, mesalamine, or balsalazide among patients with Crohn's disease. Gastroenterology 2000; 118: A891.
   Google Scholar
• Kaskas BA, Schffeler E, Lang T, et al. Gastrointestinal side effects of azathioprine in patients with inflammatory bowel disease are not related to thiopurine methyltransferase polymorphism. Gastroenterology 2000; 118: A787.
   Google Scholar
• Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 292–7.
   Google Scholar
• Seitz M. Molecular and cellular effects of methotrexate. Curr Opin Rheumatol 1999; 11: 226–32.
   Google Scholar
• Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998; 132: 830–5.
   Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000; 342: 1627–32.
   Google Scholar
• Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc 1998; 30: 1573–9.
   Google Scholar
• Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321: 845–50.
   Google Scholar
• Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 1989; 330: 1846–51.
   Google Scholar
• Stange EF, Modigliani R, Pena AS, et al. European trial of cyclosporin in chronic active Crohn's disease. Gastroenterology 1995; 109: 774–82.
   Google Scholar
• Oppong K, Record CO. Neoral may be as effective as intravenous cyclosporine in the treatment of steroid-resistant ulcerative colitis. Am J Gastroenterol 1998; 93: 1188–89.
   Google Scholar
• Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994; 106: 1429–35.
   Google Scholar
• Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995; 7: 15-25.95
   Google Scholar
• Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251–9.
   Google Scholar
• Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997; 40:443–8.
   Google Scholar
• Van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129–35.
   Google Scholar
• Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761–9.
   Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398–405.
   Google Scholar
• Farrell RJ, Shah, SA, Lodhavia PJ, Alsahli M, et al. Clinical Experience with Infliximab therapy in 100 patients with Crohn's Disease. Am J Gastoenterol 2000; 95: 3490–7.
   Google Scholar
• Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932–9.
   Google Scholar
• Hanauer SB, Rutgeerts PJ, D'Haens G, et al. Delayed hypersensitivity to infliximab (remicade) re-infusion after 2-4 year interval without treatment. Gastroenterology 1999; 116: A813.
   Google Scholar
• Bickston SJ, Lichtenstein GR, Arseneau KO, et al. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 1999; 117: 1433–7.
   Google Scholar
• Marion JF, Bodian C, Lisa T, et al. TNF microsatellite polymorphism does not predict response to infliximab in patients with Crohn's disease. Gastroenterology 2000; 118: A654.
   Google Scholar
• Sandborn WJ, Targan SR, Hanauer SB, et al. A randomized controlled trial of CDP571, a humanized antibody to TNFa in moderately to severely active Crohn's disease. Gastroenterology 2000; 118: A655.
   Google Scholar
• Feagan BG, Sandborn WJ, Baker JP, et al. A randomized double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent disease. Gastroenterology 2000; 118: A655.
   Google Scholar
• Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081–95.
   Google Scholar
• Ding L, Shevach EM. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 1992; 148: 3133–9.
   Google Scholar
• Ding L, Linsley PS, Huang LY, et al. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151: 1224–34.
   Google Scholar
• Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444–51.
   Google Scholar
• Rennick D, Davidson N, Berg D. Interleukin-10 gene knock-out mice: a model of chronic inflammation. Clin Immunol Immunopathol 1995; 76: S174–8.
   Google Scholar
• Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113: 383–9.
   Google Scholar
• Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 200; 119: 1473–82.
   Google Scholar
• Schreiber S, Fedorak RN, Wild G, et al. Safety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitis. Gastroenterology 1998; 114: A1080.
   Google Scholar
• Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996; 87: 3615–24.
   Google Scholar
• Potten CS. Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time. Stem Cells 1996; 14: 452–9.
   Google Scholar
• Qiu BS, Pfeiffer CJ, Keith JC Jr. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci 1996; 41: 1625–30.
   Google Scholar
• Gordon FH, Lai CWY, Hamilton MI, et al. Randomised double-blind placebo-controlled trial of recombinant humanised antibody to a4 integrin (antegren) in active Crohn's disease. Gastroenterology 1999; 116: A726.
   Google Scholar
• Gordon FH, Hamilton MI, Donoghue S, et al. Treatment of active ulcerative colitis with recombinant humanised antibody to a4 integrin (Antegren). Gastroenterology 1999; 116: A726.
   Google Scholar
• Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82–6.
   Google Scholar
• Hafraoui S, Lefebvre AM, Geboes K, et al. Ulcerative colitis is associated with a mucosal deficit in PPARy. Gastroenterology 1999; 116: A689
   Google Scholar
• Dubuquoy L, Desreumaux P, Peuchmaur M, et al. Activation of PPARy protects against colon inflammation by inhibiting TNFa signalling pathways. Gastroenterology2000; 118: A864.
   Google Scholar
• Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25: 653–8.
   Google Scholar
• Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635–9.
   Google Scholar
• Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo controlled. Gastroenterology 2000; 119: 305–309.
   Google Scholar
• Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998; 93: 1860–6.
   Google Scholar
• Bousvaros A, Wang A, Leichtner AM. Tacrolimus (FK-506) treatment of fulminant colitis in a child. JPediatr Gastroenterol Nutr 1996; 23: 329–33.
   Google Scholar
• Fellermann K, Herrlinger KR, Witthoeft T, et al. Tacrolimus (FK506): a new immunosup-pressant for steroid refractory inflammatory bowel disease. Gastroenterology 2000; 118: A786.
   Google Scholar
• Neurath MF, Wanitschke R, Peters M, et al. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999; 44: 625–8.
   Google Scholar
• Barnhill RL, Doll NJ, Millikan LE, et al. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leucocytes and monocytes. J Am Acad Dermatol 1984;11:814–9.
   Google Scholar
• Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998; 55: 1827–34.
   Google Scholar
• Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117: 1271–7.
   Google Scholar
• Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117: 1278–87.
   Google Scholar
• Hashimoto Y. Novel biological response modifiers derived from thalidomide. Curr Med Chem 1998; 5: 163–78.
   Google Scholar
• Marriott JB, Westby M, Cookson S, et al. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol 1998; 161: 4236–43.
   Google Scholar
• Pullan RD, Rhodes J, Ganesh S, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994; 330: 811–5.
   Google Scholar
• Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 364–71.
   Google Scholar
• Thomas GA, Rhodes J, Ragunath K, et al. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis. Eur J Gastroenterol Hepatol 1996; 8: 769–76.
   Google Scholar
• Madretsma GS, Donze GJ, van Dijk AP, et al. Nicotine inhibits the in vitro production of interleukin 2 and tumour necrosis factor-alpha by human mononuclear cells. Immunopharmacology 1996; 35: 47–51.
   Google Scholar
• Pullan RD. Colonic mucus, smoking and ulcerative colitis. Ann R Coll Surg Engl 1996; 78: 85–91.
   Google Scholar
• Compton RF, Sandborn WJ, Lawson GM, et al. A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration Aliment Pharmacol Ther 1997; 11: 865–74.
   Google Scholar
• Green JT, Thomas GA, Rhodes J, et al. Nicotine enemas for active ulcerative colitis — a pilot study. Aliment Pharmacol Ther 1997; 11: 859–63.
   Google Scholar
• Sandborn WJ, Tremaine WJ, Leighton JA, et al. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther 1997; 11: 663–71.
   Google Scholar
• Gaffney PR, O'Leary JJ, Doyle CT, et al. Response to heparin in patients with ulcerative colitis. Lancet 1991; 337: 238–9.
   Google Scholar
• Evans RC, Wong VS, Morris AI, et al. Treatment of corticosteroid-resistant ulcerative colitis with heparin—a report of 16 cases. Aliment Pharmacol Ther 1997; 11: 1037–40.
   Google Scholar
• Korzenik JR, Robert ME, Bitton A, et al. A multicenter, randomized, controlled trial of heparin for the treatment of ulcerative colitis. Gastroenterology 1999; 116: A752.
   Google Scholar
• Korzenik JR. IBD: a vascular disorder? The case for heparin therapy. Inflamm Bowel Dis 1997; 3: 87–94.
   Google Scholar
• Steinhart AH, Hiruki T, Brzezinski A, et al. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 1996; 10: 729–36.
   Google Scholar
• Breuer RI, Soergel KH, Lashner BA, et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut 1997; 40: 485–91.
   Google Scholar
• Eliakim R, Karmeli F, Razin E, et al. Role of platelet factor in ulcerative colitis: enhanced production during active disease and inhibition by sulphasalazine and prednisone. Gastro-enterology 1988; 95: 1167–72.
   Google Scholar
• Meenan J, Grool TA, Hommes DW, et al. Lexipafant (BB-882), a platelet activating antagonist amelerioates mucosal inflammation in ulcerative colitis. Eur J Gastroenterol Hepatol 1996; 8: 569–83.
   Google Scholar
• Jones NL, Roifman CM, Griffiths AM, et al. Ketotifen therapy for acute ulcerative colitis in children: a pilot study. Dig Dis Sci 1998; 43: 609–15.
   Google Scholar
• Simmonds NJ, Rampton DS. Inflammatory bowel disease-a radical view. Gut 1993; 34: 865–8.
   Google Scholar
• Emerit J, Pelletier S, Tosoni-Verlignue D, et al. Phase II trial of copper zinc superoxide dismutase (CuZnSOD) in treatment of Crohn's disease. Free Radic Biol Med 1989; 7: 1459.
   Google Scholar
• Rask-Madsen J. From basic science to future medical options for treatment of ulcerative colitis. Eur J Gastroenterol Hepatol 1997; 9: 864–71.
   Google Scholar
• Hawthorne AB, Daneshmend TK, Hawkey CJ, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992; 33: 922–8.
   Google Scholar
• Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996; 334: 1557–60.
   Google Scholar
• Shulman DI, Hu CS, Duckett G, et al. Effects of short-term growth hormone therapy in rats undergoing 75% small intestinal resection. JPediatr Gastroenterol Nutr 1992; 14: 3–11.
   Google Scholar
• Zhang W, Bain A, Rombeau JL. Insulin-like growth factor-I (IGF-I) and glutamine improve structure and function in the small bowel allograft. J Surg Res 1995; 59: 6–12.
   Google Scholar
• Byrne TA, Persinger RL, Young LS, et al. A new treatment for patients with short-bowel syndrome: growth hormone, glutamine, and a modified diet. Ann Surg 1995; 222: 243–54.
   Google Scholar
• Slonim AE, Bulone L, Damore MB, et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000; 342: 1633–7.
   Google Scholar
• Dubinsky MC, Hassard PV, Abreu MT, et al. Thioguanine (6-TG): a therapeutic alternative in a subgroup of IBD patients failing 6-mercaptopurine. Gastroenterology 2000; 118: A891.
   Google Scholar
• Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, et al. Local administration of antisense phosphoothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996; 2: 998–1004.
   Google Scholar
• Jobin C, Panja A, Hellerbrand C, et al. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kB super-repressor in human intestinal epithelial cells. J Immunol 1998; 160: 410–18.
   Google Scholar
• Hogaboam CM, Vallance BA, Humar A, et al. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest 1997; 100: 2766–76.
   Google Scholar